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Immunosuppressive drugs are commonly used for the treatment of inﬂammatory bowel disease. Patients receiving immuno-
suppressants are susceptible to a variety of infections with opportunistic pathogens. We present a case of skin infection with
Mycobacterium chelonae in a 60-year-old Caucasian woman with ulcerative colitis who had been treated with corticosteroids and
azathioprine. The disease manifested with fever and rash involving the right leg. Inﬂiximab was administered due to a presumptive
diagnosis of pyoderma gangrenosum, leading to worsening of the clinical syndrome and admission to our hospital. Routine
cultures from various sites were all negative. However, Ziehl-Neelsen staining of pus from the lesions revealed acid-fast bacilli, and
culture yielded a rapidly growing mycobacterium further identiﬁed as M. chelonae. The patient responded to a clarithromycin-
based regimen. Clinicians should be aware of skin lesions caused by atypical mycobacteria in immunocompromised patients with
inﬂammatory bowel disease. Furthermore, they should be able to thoroughly investigate and promptly treat these conditions.
1.Introduction
Immunosuppressive drugs, consisting of corticosteroids,
immunomodulators, and biological factors, are the mainstay
of treatment for inﬂammatory bowel disease (IBD). These
medications leadtoastateofimmunosuppression, thesever-
ityofwhichdependsuponthespeciﬁcdrug,thedoseadmin-
istered, and the duration of treatment [1]. Patients receiv-
ing immunosuppressants become susceptible to infections,
caused not only by common pathogens, but also, by various
opportunistic microorganisms.Thelattermaycauseunusual
clinicalsyndromes,thusgeneratingdiagnosticandtherapeu-
tic challenges, as they are easily confused with the variety
of extraintestinal manifestations of Ulcerative Colitis (UC)
and Crohn’s disease (CD) [2]. Herein, we describe a case
of skin infection with Mycobacterium chelonae in a woman
who was under long-term immunosuppressive treatment
for UC. The lesion was initially misdiagnosed as pyoderma
gangrenosum resulting in initiation of anti-TNF treatment.
The ﬁnal diagnosis was achieved only when microbiological
testing with optimal culture conditions was applied.
2. Case Presentation
A 60-year-old female, with a 12-year history of UC involving
the entire colon, was admitted to our hospital for evaluation
of skin lesions and low-grade fever. The patient had been
receiving 5-ASA preparations, since UC diagnosis, and corti-
costeroidsandazathioprineforthelast3years.Atadmission,
UC was in clinical remission and the patient was on 16 mg of
methylprednisolone and 150mg azathioprine daily.
Four months prior to admission, while intestinal disease
was in remission, the patient noticed several painless,
erythematous nodules on her right lower extremity. There
was no history of prior trauma. Local corticosteroids had no
beneﬁcial eﬀect. A month and a half later, low-grade fever
(up to 37.6◦C) was noticed. An incision was made in one of
the lesions, pus obtained and sent for culture, which grew2 Case Reports in Medicine
Figure 1: Multiple violet skin lesions in the right lower extremity of
the patient. Pitting edema of the ankle and foot is also demonstra-
ted. The inlet depicts one of the lesions, where an oriﬁce leading to
a pus collection is shown.
Staphylococcus aureus. Two-week treatment with doxycycline
resulted in no clinical improvement. The diagnosis of pyo-
dermagangrenosum(withpossiblebacterialcontamination)
was considered and treatment with inﬂiximab initiated in a
classical induction scheme (0–2–6wks). Before starting ther-
apywithinﬂiximab,atuberculinskintestwasperformedand
reported negative, whereas a chest X-ray was unremarkable.
Ten days after the second infusion of inﬂiximab, the patient
noticed worsening of the skin lesions along with high fever
(38.7◦C) and was admitted to our hospital.
Clinical examination revealed an obese patient (BMI:
32) with temperature of 37.7◦C. Inspection of the lower
extremities showed multiple, painless, erythroviolet, round,
and clearly delineated nodular lesions, 2–5cm in size, which
were localized in the lower right leg and foot (Figure 1).
There was seropurulent discharge from some of the lesions.
Laboratory investigations revealed mild leukocytosis (WBC:
11,900k/μL, P: 85%, L: 7%), with elevated erythrocyte sedi-
mentation rate (60mm/hr, normal range 0–20mm/hr) and
C-reactive protein (12.6mg/dL, normal range 0–5mg/dL)
with no abnormalities on biochemical and urine tests.
Colonoscopy revealed endoscopic features consistent
with quiescent ulcerative colitis, which was conﬁrmed by
histological examination of colon biopsies that showed
absence of active inﬂammation and signs of chronic injury
with disturbed mucosal architecture.
As the patient experienced persistent fever (37.8 to
38.2◦C), weperformedextensive searchforinfectious agents.
Blood, urine, and stool cultures as well as chest X-rays
were repeatedly negative. Tuberculin skin test was negative
and CT-scan of the lower abdomen was unremarkable.
MRI scan of the lower right limb and three-phase bone
scintigraphy with 99mTc-MDP revealed signs consistent with
inﬂammation of the skin and subcutaneous tissue but no
evidence of bone involvement or abscess formation. A skin
biopsy showed ﬁndings consistent with a granulomatous
inﬂammatory process of the skin, without necrosis.
Pus was collected from one of the draining lesions.
Direct microscopic examination after Ziehl-Neelsen staining
was positive for acid-fast bacilli (Figure 2). Cultures of the
purulent material on both blood agar and Lowenstein media
Figure 2: Ziehl-Neelsen staining of pus obtained from a draining
lesion reveals multiple acid-fast bacilli.
Figure 3: Photograph taken 6 months after treatment shows heal-
ingoftheskinlesionswithcompletecessationofdischargeandresi-
dual discoloration.
yielded a rapidly growing, nontuberculous mycobacterium.
Treatment was initiated with intravenous cefoxitin 3gqid,
clarithromycin 500mg bid, and amikacin 1gqd. Two weeks
later the patient was signiﬁcantly improved with cessation
of fever and diminishing of cutaneous lesions. Following
the identiﬁcation of the microorganism as Mycobacterium
chelonae in a reference laboratory and susceptibility testing,
she was discharged home on clarithromycin 500mg bid
for an additional six months. Administration of inﬂiximab
and azathioprine was terminated and corticosteroids rapidly
tapered and discontinued. Upon several follow-up visits, the
patient remained afebrile and the cutaneous lesions were
gradually eliminated (Figure 3).
3. Discussion
The present case illustrates the diﬃculties in managing
dermatological manifestations in patients with IBD. The
diﬀerential diagnosis should include not only those skin
conditions that occur more frequently in IBD (most notably
erythema nodosum and pyoderma gangrenosum) but also
treatment-associated lesions [3]. Among the latter, skin
infections should always be considered in patients who
receive immunosuppressive regimens, particularly in theCase Reports in Medicine 3
settingofanewrashandfever[2].Suchinfectionsaccounted
for21% of all and 40.5% of serious infections in alarge series
of patients receiving anti-TNF agents [4].
In recent years, the risk for immunosuppression-induced
reactivation of tuberculosis has been well documented
and led to pretreatment testing for latent infection and
prophylactic chemotherapy of individuals at risk [5]. On
the other hand, infections with atypical mycobacteria are
less recognized outside the infectious diseases specialty [6].
Nevertheless, studies from large databases of patients on
immunosuppressants have reported one case of atypical
mycobacterial infection for every 4–10 cases of tuberculosis
[7]. Interestingly, a recent survey reported twice as many
infections with nontuberculous mycobacteria as compared
to cases of tuberculosis in patients receiving anti-TNF
agents for various conditions [8]. Similar to our patient,
nontuberculous mycobacterial disease frequently localizes to
the skin and soft tissues [9]. The microorganism responsible
for the skin infection in our patient was M. chelonae.T o
our knowledge, no published report of such infection exists
in the IBD literature. However, in recent studies in anti-
TNF-treated patients with various conditions, M. chelonae
accounted for 10% of all mycobacterial or 4% of non-
tuberculous mycobacterial infections, respectively [8, 9]. In
the IBD population, infections with atypical mycobacteria
such as M. gordonae, M. fortuitum, M. marinum,a n dM.
xenopi have been reported [10–12].
Recently, Toruner et al. studied the presentation of
and risk factors for opportunistic infections among IBD
patients [10]. Although all immunosuppressive drugs (cor-
ticosteroids, immunomodulators, biologicals) increased the
risk of infection, this risk was disproportionally elevated
when combinations of drugs were administered. Caution,
therefore, is needed when prescribing such medications and
regular reassessment is required in order to discontinue any
unnecessary therapies. This is of particular relevance to the
present case, as our patient was treated with corticosteroids
foranextendedperiod,beforeadmissiontoourunit.This,in
combination to azathioprine administration, most probably
led to the development of mycobacterial infection. The
ability to discontinue both medications after the diagnosis
of M. chelonae infection, without a ﬂare in disease activity,
emphasizes the need for constant cost/beneﬁt evaluation in
the treatment of IBD patients. In particular, current guide-
lines for the treatment of IBD clearly state that prolonged
administration of corticosteroids to maintain remission is
not an acceptable option. Corticosteroid-sparing agents such
as thiopurines and methotrexate should be used followed
by early introduction of biologicals in treatment failures.
Furthermore, the development of a febrile skin lesion in our
patient was mistakenly considered as pyoderma gangreno-
sum, a diagnosis which led to inﬂiximab administration
and the eventual unmasking of the mycobacterial infection.
Nevertheless, the occurrence of pyoderma gangrenosum in
our patient was highly unlikely, given the corticosteroid
use and the quiescent phase of colitis. Had a colonoscopy
been performed in our patient before the initiation of
inﬂiximab, it might have helped therapeutic decisions. If
no active inﬂammation were seen, it might have questioned
the diagnosis of pyoderma gangrenosum and prompted
early consultation by a dermatologist and/or infectious
diseases specialist. In fact, such an approach is strongly
recommended by current guidelines on the management of
infectious complications in IBD patients receiving immuno-
suppressants [2]. This is of particular importance as skin
infections, including those caused by atypical mycobacteria,
can easily be confused with the various dermatological
manifestations of IBD. Similar to the present case, the initial
clinical impression for these lesions has been reported very
often to be misleading [13]. In addition, gastroenterologists
may not be familiar with the speciﬁc conditions required
for the growth of these microorganisms in culture. In
our case, initial cultures were performed in regular media
and reported negative, as no growth was observed after
incubation for 48 hours. Nevertheless, when the possibility
of atypical mycobacteria was considered, cultures were left
to incubate for several days, resulting to the growth of M.
chelonae.Indeed,ithasbeenrecentlysuggestedthatinfection
with non-tuberculous mycobacteria must be suspected when
routine microbiological tests are negative [14].
4. Conclusion
We present a rare case of skin infection with M. chelonae
in a patient with IBD. It is important that clinical gastroen-
terologists recognize atypical mycobacterial infections in this
group of patients and be able to thoroughly investigate and
aggressively treat those conditions.
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